360 High-Risk Vulnerability Immunization Tool V2.0 vs ThreatLocker Platform: Side-by-Side Comparison (2026)
Features, pricing, ratings, and pros & cons — compared head-to-head.
360 High-Risk Vulnerability Immunization Tool V2.0 is a commercial endpoint protection platform tool by 360 Security Group (Qihoo 360). ThreatLocker Platform is a free endpoint protection platform tool. Compare features, ratings, integrations, and community reviews side by side to find the best endpoint protection platform fit for your security stack.
CST VerdictBased on our analysis of NIST CSF 2.0 coverage, core features, company size fit, deployment model, here is our conclusion:
360 High-Risk Vulnerability Immunization Tool V2.0
Startups and SMBs with Windows-heavy infrastructure and patching backlogs should run 360 High-Risk Vulnerability Immunization Tool V2.0 first; it immunizes against the specific CVEs that drive ransomware campaigns (MS17-010, CVE-2019-0708) without requiring immediate OS updates. The tool supports Windows 7 through current versions and deploys on-premises, meaning air-gapped networks can actually use it. Skip this if you're looking for NIST PR.PS coverage beyond platform hardening,this tool stops known exploits, not supply chain attacks or firmware-level threats.
Security teams managing distributed workforces or remote-heavy environments should evaluate ThreatLocker Platform for its application whitelisting enforcement, which stops ransomware execution at the kernel level before it spreads across your fleet. The zero-trust default-deny posture means you're blocking malware by architecture, not detection signatures, which matters when your endpoints can't phone home to a central console every few seconds. Skip this if you need deep behavioral analytics or threat hunting; ThreatLocker prioritizes prevention over investigation, so forensic visibility lags behind traditional EDR platforms.
